A new drug combination has delivered encouraging results in patients with advanced pancreatic cancer, with tumours disappearing from scans in some participants and stopping growth in a small study.
The findings have raised hopes of a future advance against one of the deadliest forms of cancer, with further investigation required.
The small study examined daraxonrasib, a daily pill, in combination with chemotherapy. Among the 61 participants, whose pancreatic cancer had spread to other parts of the body, tumours stopped growing in around 90 per cent of cases.
In this small group, more than 60 per cent experienced tumour shrinkage or disappearance, while around eight per cent had no detectable cancer on CT scans.
Patients were followed for an average of 18 months. One year after beginning treatment, 76 per cent were still alive. This compares with an estimated 40 to 45 per cent of patients surviving for a year when treated with chemotherapy alone.
The findings were presented by Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
Describing the results, Park highlighted the number of tumours that had become undetectable despite the cancer having spread.
"We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," he said.
How might the treatment target cancer?
Daraxonrasib belongs to a class of treatments known as KRAS inhibitors. It targets specific mutations in the KRAS gene, which are found in most pancreatic cancers and help drive tumour growth.
By locking on to these mutations and switching off their activity, the drug aims to prevent cancer cells from continuing to grow.
The latest findings build on earlier research published this year, which found that daraxonrasib could almost double survival in patients with aggressive forms of pancreatic cancer. Median survival increased from 6.7 months to 13.2 months in that study.
Researchers are also exploring whether the approach could have applications in other cancers carrying similar KRAS mutations.
What does this mean?
Despite the encouraging results, doctors have warned against interpreting the findings too positively.
It remains unclear how long the treatment can keep the cancer under control or whether tumours that have disappeared from scans will return. Longer follow-up and further clinical studies will be needed to establish whether the responses can translate into lasting remission.
Pancreatic cancer remains particularly difficult to treat, especially once it has spread to other organs. Around half of patients die within three months of diagnosis, while only about three per cent of those with advanced disease survive for five years.
Michelle Mitchell, chief executive of Cancer Research UK, described the findings as the biggest leap forward seen in decades for pancreatic cancer patients, but stressed that more research was needed.
She said the results could eventually offer hope to people facing one of the deadliest and most difficult-to-treat cancers, while potentially opening up new treatment possibilities for other cancers with KRAS mutations.
Further trials will be needed before the treatment can be assessed for use on the NHS. For now, the findings offer a promising development in a cancer where treatment options and long-term survival have remained limited.












